Skip to main content
Figure 4 | Molecular Cancer

Figure 4

From: Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms

Figure 4

Quizartinib reduces the proportion of viable cells in samples of native leukemia cells. Patient samples were cultured in DMEM containing 20% FBS and treated with different concentrations of quizartinib for 48 hours. (A) The plot of one patient is shown. The mononuclear cell fraction was gated in a FSC/SSC scatter and viability was confirmed using an annexin V/propidium iodide (PI) stain demonstrating negativity for annexin V and PI. (B) Relative reduction of the proportion of viable cells in response to quizartinib was assessed by flow cytometry. A dose-effect plot of all tested concentrations of quizartinib is shown on the right. Estimated IC50s by non-linear regression analysis of all tested patient samples are provided in Table 2.

Back to article page

Molecular Cancer

ISSN: 1476-4598